Securing patent protection in the U.S. is a significant milestone for PeptiSystems and strengthens our position in a strategically important market. We are now advancing into the next phase of our development, with a clear focus on enabling large-scale peptide manufacturing. Demand for peptide-based therapeutics, including GLP-1 analogs, continues to grow rapidly, placing increasing demands on production capacity, cost efficiency, and scalability. Our solution is designed to meet these needs, offering a more cost- and resource-efficient, scalable alternative to conventional manufacturing methods.

We are scaling our commercial operations and expanding our global presence. Ole’s experience from international life science companies and global organizations will be valuable as we continue to grow the business. We are pleased to welcome him to the Board of Directors.

It’s encouraging to see PeptiPilot® selected as the synthesis system for this research at the University of Zurich. Aggregation has long been a bottleneck in peptide production, and this study shows how our flow-based technology helps address that challenge. By bridging the gap between lab-scale research and industrial peptide manufacturing, PeptiPilot® enables a faster and more sustainable path to next-generation therapeutics.

We are pleased to welcome Rubicon Healthcare Partners as a new shareholder in PeptiSystems. Their global life science experience and Nordic presence will be a valuable asset as we take the next steps in driving commercialization and scale our technology for industrial applications. This investment reflects confidence in our team and our strategy to drive growth in a rapidly expanding market.

We’re thrilled to welcome Helena Strigård and Nick Roelofs to the board. Helena has a unique ability to navigate the intersections of industry, policy, and finance – and has played a key role in developing Sweden’s life science ecosystem. Nick brings scientific insights, business leadership, and strategic depth, with deep experience in global growth and partnerships. Their combined strengths will further reinforce our position as we scale our technology for large-scale peptide production.

By integrating a proven and high-quality column into our platform, we can offer a complete, ready-to-use solution that helps customers accelerate development and reduce risk. It’s a strategic step that strengthens our offering and supports future growth in both research and manufacturing applications.

We see this partnership as a natural step in bringing next-generation peptide solutions to the TIDES market. By combining our column expertise with PeptiSystems’ innovative synthesis platform, we’re enabling customers to access a complete, integrated solution.

We are thrilled to welcome Mårten Bergström to our PeptiSystems leadership team. Mårten brings a wealth of experience and a deep commitment to excellence, which will be invaluable as we continue refining our engineering and quality standards. His expertise and leadership will play a key role in driving innovation and enabling us to consistently deliver the highest quality to our customers.

This funding is a pivotal milestone for PeptiSystems. It enables us to expand our production capacity, scale operations globally, and continue developing technologies that not only address growing demand but also align with the industry’s drive for sustainability and innovation. We are grateful for the strong support from our investors and excited to embark on this next phase of growth.

We are excited to join forces with Gene, a respected distributor with a strong presence from 30 years of doing business in the Greater China region. Our agreement with Gene will ensure that more customers have access to our best-in-class peptide and oligonucleotide synthesizers, furthering our mission to support PeptiSystems’ transformational flow through technology and strategic expansion in this fast-growing market.

We are extremely enthusiastic about the partnership with ATG Service. Their expertise and nationwide presence align perfectly with our commitment to delivering superior technology and exceptional customer care. We couldn't expect a better partner to support us in our strategy to maintain high customer satisfaction. The collaboration with ATG Service will allow PeptiSystems to develop even faster in the US and Canadian markets.

We are thrilled to have concluded this investment round of 20 MSEK, which demonstrates the strong support from our investors. The raised capital will empower us to scale our operations, ultimately driving enhanced value for our customers and stakeholders. We are happy to have new strong investors on board, Henrik Didner through Monesi Förvaltning AB and Nolsterby Invest AB, together with continued support from our existing investors Almi Invest and PÄAB.

I am very excited to have joined PeptiSystems and look forward to leading the company on our continued expansion journey. I am impressed how PeptiSystems has transferred their deep knowledge in oligonucleotide synthesis to also successfully apply the solid-phase flow through column technology to peptide manufacturing processing.

We are thrilled that CordenPharma has decided to work with PeptiSystems to evaluate our technology. Corden Pharma’s expertise and feedback is very valuable for us in the continued development of these instruments and in our mission towards greener and more efficient peptide manufacturing.

We have received several orders of both small and large-scale instruments and are getting a lot of enthusiastic feedback when speaking to customers. It's exciting to finally be able to introduce these instruments to the market after many years of development.